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Abstract 
Objectives:  To assess the long-term (LT) patient-reported outcomes and adverse events(AE) 
following transobturator tension-free vaginal tape(TO-TVT) 
Design: Postal follow-up of the E-TOT randomised controlled trial(RCT)  
Setting: A tertiary urogynaecology center in the UK; all procedures took place in 2005 to2007. 
Population: 341 Women were randomised to undergo either “inside-out” TVT-O (Ethicon 
Inc.,Somerville,NJ,USA) or “outside-in” TOT-ARIS (Coloplast Corp., Minneapolis,MN,USA).  
Methods: Long-term (median 9-years) follow-up, using validated symptom severity and Qol 
questionnaires. Statistical analysis was performed using SPSS v22.0(IBM Corp.,Armonk, 
NY,USA) and GraphPad Statistics-2014. 
Main Outcome Measures: Primary outcome was patient-reported success rate defined as “Very 
Much/Much Improved” on the Patient's Global Impression of Improvement (PGI-I) scale. 
Secondary outcomes included impact on women’s QoL and sexual function; adverse events and 
re-operations for SUI.  
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Results: The adjusted-response rate was 67.8%; median follow-up was 9.2-years. The overall 
patient-reported success rate was 71.6% with further 14% reporting “improvement”; and no 
significant difference between inside-out and outside-in groups (p=0.76,OR:0.8676, 
95%CI:0.4744,1.5865). The success rate showed significant reduction compared to 1-year results 
(71.6%vs.80%; p=0.004) but clinically insignificant reduction when compared to the 3-years 
(71.6%vs.73.1%). A total of 7.96 % underwent further continence surgery; tape extrusion/ 
erosion rate was 4.5%; groin pain/discomfort was reported in 4.32% with only 1.4% requiring 
treatment.  
Conclusions:  This is the largest and longest follow-up randomized trial of TO-TVT. TO-TVT is 
associated with 71.6% patient-reported success rate, 4% groin pain/discomfort and 8% 
continence re-operation rate at median of 9-years follow-up. The success rate is almost stable 
after 3-years.  
 
Keywords: ARIS, tension-free vaginal tapes, transobturator tape, TVT-O, Stress urinary 
incontinence. 
Tweetable abstract: The success rate for TO-TVT is 71% at 9-years and is almost stable after 3-
years; 8% required repeat surgery.  
Trial registration number and link to the registration web page: The study was registered on 
www.clinicaltrials.gov  and registration number is: NCT00136071. The registration web page 
link is:  https://clinicaltrials.gov/ct2/results?term=NCT00136071&Search=Search  
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Introduction: 
There is a paucity of data on the long-term outcomes of transobturator tension free vaginal tape 
(TO-TVT) in the surgical treatment of female stress urinary incontinence (SUI). In the UK, the 
National Institute for Health and Clinical Excellence (NICE)
1
 and the interim reports on 
transvaginal mesh for SUI and prolapsed surgery, both in Scotland
2  
and England
3 
highlighted the 
lack of long-term outcomes data for mid-urethral slings(MUS) in general and TO-TVT in 
particular. They emphasized the importance of directing future research to address this gap in the 
literature. Long-term data on MUS are primarily derived from the clinical trials assessing retro-
pubic tension-free vaginal tapes (RP-TVT)
4,5
 however long-term outcomes for TO-TVT are now 
emerging
6,7
. 
 
The E-TOT
8 
is the largest RCT assessing the outcomes of TO-TVT (n=341women); and the only 
adequately powered RCT in the literature to compare inside-out versus outside-in approaches. 
We have previously reported the outcomes at 1and 3-years follow-up
8,9
. At 3-years, the patient 
reported success rate, was 73.1% with no significant difference between groups (Inside-out 73.18 
% vs. Outside-in 72.3%; OR: 0.927; 95%CI 0.552–1.645; p=0.796)9. In the E-TOT study we 
used the Patient Global Impression of Improvement (PGI-I) as the primary outcome as it 
provides a robust, validated and more global review of the treatment outcome, and more fully 
encompassing the range of benefits and potential harms of the treatment. Several studies have 
established its validity to assess disease severity, bother and improvement after treatment in 
women with SUI. 
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In this study we aim to assess the long-term (LT) outcomes and adverse events (AE) following 
TO-TVT as a whole cohort and to compare the effectiveness of inside-out versus outside-in 
approaches. 
 
Methods: 
 Long-term (LT) follow-up of the E-TOT RCT (Fig1) conducted between April-2005 and April-
2007 in a tertiary urogynaecology center in the UK. The E-TOT protocol was registered on 
www.clinicaltrials.gov and ethics committee approval was obtained for this LT follow-up. All 
eligible participants with urodynamic SUI or stress predominant mixed UI, who failed or 
declined pelvic floor muscle training and opted for a MUS procedure, within the study period, 
were invited to participate. Women with pelvic organ prolapse (≥POP-Q stage-2), concomitant 
surgery, previous pelvic irradiation, relevant neurological conditions (such as multiple sclerosis) 
were excluded.  
 
Participants (n=341) were randomised to undergo either TVT-O(Ethicon Inc.,Somerville, 
NJ,USA) for the inside-out approach or TOT-ARIS(Coloplast  Corp.,Minneapolis, MN,USA) for 
the outside-in approach. TO-TVT was performed as originally described.
10,11
 Preoperative 
assessment included urodynamic assessment and completion of the Birmingham Bowel Urinary 
Symptom-22 questionnaire
12
; King's Health Questionnaire (KHQ)
13,14
 and Prolapse Incontinence 
Sexual Function Questionnaire (PISQ-12)
15
.  At 1,3 and 9-years follow-up, participants were 
contacted by post and completed the above questionnaires and in-addition, PGI-I
16
; International 
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Consultation on Incontinence Questionnaire-Short Form(ICIQ-SF)
17
; Urgency Perception 
Scale(UPS)
18
; questions on adverse events(AE) and further continence surgery. 
 
Total of 314 participants were included in this LT follow-up; 22-participants who received 
further continence surgery within the first 3-years were included in this study and considered as 
failures. 292-participants were contacted between April-2014 and February-2015. Strategy for 
non-responders included another round of postal questionnaire. Persistent non-responders 
received a further short questionnaire and/or phone interview. 
 
Similar to 1 and 3-years reports, the primary outcome was patient-reported success rate based on 
a response of “Very/Much Improved” to the PGI-I. Secondary outcomes were further continence 
surgery; impact on quality of life (QOL); sexual function; AE such as groin/thigh pain and tape 
erosions/extrusions; and risk factors for late failures.  
 
We anticipated ≥50% response rate; assuming 180 respondents (90 in each arm) and a success 
rate of 70% for inside-out TVT-O, as reported by Angioli et al
19
, this would allow 80% power to 
detect a 20% difference in the patient-reported success rates between the two groups. Categorical 
variables were compared using chi-square test. Within-group comparison was undertaken using 
Wilcoxon and Mann-Whitney tests. Risk factors for late failures were assessed in a sequential 
regression model. All statistical analysis was performed using SPSSv.22.0 (IBM 
Corp.,Armonk,NY,USA)and GraphPad Statistics 2014. 
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Results: 
314 participants were included in this LT study; 7 participants were excluded (deceased n=4 and 
withdrawn n=3). LT follow-up was completed by 208 (Outside-in n=104 vs. Inside-out n=104); 
the adjusted response rate is 67.8% (Figure 1). The mean age at follow-up was 61-years 
/SD10.12 (median59; range41-87). The median follow-up was 9.2-years (range 81-119month; 
mean 109.8month /SD15.22). All missing data were confirmed to be missing at random and were 
handled by multiple imputation and sensitivity analysis. . 
 
- Patient-Reported Success: The overall patient-reported success rate, defined as 
Very/Much Improved on PGI-I, was 71.6% with no significant difference between groups 
(Outside-in 73.1%(n=76) vs Inside-out 70.2%(n=73); p=0.76; OR:0.867, 95% CI:0.474, 
1.586). A further 14% (n=30) reported “Improvement”. These results pertained on random 
multiple imputation and multiple sensitivity analysis (Table 1). The patient-reported success 
rate using last observation carried forward  for missing data was 72.6% with no significant 
differences between groups (Outside-in 75.5% vs Inside-out 69.9%; p=0.29) (Table 1). 
 
Compared with the 1-year outcomes, there was a significant reduction in the patient-reported 
success rate at 9-years (80% versus 71.6%, p=0.004). However compared to the 3-years follow-
up, there was only a modest 1.5% reduction over 6-years (73.1% versus 71.6%) (Figure 2a). A 
number of potential risk factors for “late failure” (i.e. period between the 3 & 9-years follow-up) 
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were analysed including age, BMI, OAB symptoms, previous continence surgery and MUCP; no 
independent risk factors were identified on sequential regression analysis.  
 
Further analysis for women within who did not meet the definition of success (n=59) showed 
PGI-I responses of “Improved(n=30)”, “Same(n=10)”, “Worse(n=10)”, “Very Much 
Worse(n=9)”. We further analyzed ICIQ-SF and BBUQ-22 responses in this group, this showed 
symptoms of MUI in 47 women, symptoms of pure UUI and pure SUI in 3 and 4 women 
respectively.   
 
- Adverse events (AE): AE were assessed amongst the respondents only (n=208) and 
showed: 9.61% de-novo urgency rate of which (84%) were mild or moderate on UPS. Late 
tape extrusion/ erosions i.e. after 3-years was reported in 1.9% (n=4). However the total 
erosion/extrusion rate over the period of follow-up, in the whole E-TOT cohort is 4.5% 
(n=14/314).      
 
Groin or inner thigh pain/discomfort (defined by the patient having any level of thigh and/or 
groin pain/ discomfort) were reported in 4.32% (Inside-out n=4 vs. Outside-in n=5): two 
participants (1%) reported to be receiving analgesia while one participant (0.4%) underwent 
complete tape removal for a combination of vaginal extrusion and pain. The latter participant 
reported a background of arthritis for which she was also receiving analgesia. Table 2 shows all 
AE at 9 years. 
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- Further Continence Surgery: A total of 25 participants (7.96 %) underwent further 
surgical treatment for SUI over the entire follow-up period in the whole E-TOT cohort 
(n=25/314). However only 1% (n=3) underwent repeat surgery between the 3and 9-years 
follow-up (Figure 2b). The surgical details of the repeat continence surgery and their 
outcomes are presented in Table S1: the patient-reported success rate in this group was 
relatively poorer (65%) however it was difficult to draw meaningful analysis due to the 
relatively small cohort and the heterogeneity of the type of further continence surgery 
performed. 
 
- QoL and Sexual Function: KHQ was completed by 171 participants. Clinically 
significant improvement in QoL (defined as≥10 points improvement) was seen in 76.8% with 
no evidence of significant differences between both groups (OR 0.566; 95%CI0.292-1.202; 
p=0.121). 87 participants (44.8%) completed PISQ-12 questionnaires (both pre and post-
operative). The sexual function score on PISQ-12 showed improvement in 61% and 
deterioration in 34.5% with no evidence of significant difference between groups (p=0.113) 
Table S2. 
 
DISCUSSION: 
The E-TOT study is the largest RCT to report long-term outcomes for TO-TVT with the ability 
to compare the patient-reported outcomes at different follow-up points. 
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Main Findings: The results show that the overall patient-reported success rate of TO-TVT was 
71.6% at median follow-up of 9-years, with no significant difference between groups; the results 
pertained on multiple sensitivity analyses.  Further 14% reported “Improvement” however unlike 
Nilsson etal
5
, we did not consider “improved” as a successful outcome to avoid over-estimation 
of success rates. Nilsson etal
5 
reported on a small population(n=58) who underwent RP-TVT 
with 17years follow-up; the patient-reported success rate was 87%. The success rate showed 
significant reduction compared to 1-year results but clinically insignificant reduction when 
compared to the 3-years. Clinically significant improvement in QoL was seen in the majority of 
patients (76.8%) with no evidence of significant differences between both groups A total of 8% 
underwent further continence surgery. Adverse events included: tape extrusion/ erosion rate was 
4.5%; groin pain/discomfort in 4.32% with only 1.4% requiring treatment. 
 
Strengths and Limitations 
The LT follow-up for a large homogenous cohort of women and the clinically applicable 
results are major strengths. The good response rate of 67.8% is quite representative of the 
whole cohort. The E-TOT RCT is adequately powered, with robust inclusion and exclusion 
criteria and standardized postoperative assessment using validated tools. Patient reported 
outcomes were obtained by postal a questionnaire which essentially eliminates the assessor’s 
bias and reduces the participants’ visits to hospital which in-turn reduces the attrition rates. 
The assessment of the AE in our study was self-reported which may be seen as a limitation, 
however this approach excludes the assessor bias. We acknowledge the limitation of the data 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
on long-term pain/discomfort - further qualitative study is required to assess those participants 
with pain for severity; relation to the procedure; impact on QoL and any possible regret. The 
single center design can be seen as a limitation however the procedures were performed by 6-
surgeons of varying experience ensuring generalizability of the results.  The lack of objective 
assessment for cure of UI is a limitation of this study. 
 
Interpretation in light of other evidence: 
The success rate in the E-TOT study is similar to RP-TVT at 10-years: Groutz etal
20
 underwent a 
telephone follow-up at 10-years and reported an overall patient-reported success rate of 65% 
while 78% reported cure of SUI. Similarly, Aigmueller etal
21
 assessed 140 women at 10-years 
following RP-TVT and reported a patient-reported cure rate of 57% with further 23% reporting 
“improvement”.  Svenningsen etal22 showed higher patient-reported cure rates(76%) at 10-years 
for a large cohort(n=483) who underwent RP-TVT.  
 
Two recent observational studies reported the 10-years outcomes for TO-TVT: Serati etal
7 
reported the results of a multicenter study (n=160); the patient-reported and objective cure rates 
were 97% and 92% respectively. Their outcomes were clearly more favorable than the E-TOT 
study despite using the same definition of success, however inside-out TO-TVT was the only 
procedure performed in their study and their response rate was almost 95%. Ulrich etal
6 
reported 
the 10-years outcomes for inside-out TO-TVT in 2-centers (n=71); the patient-reported and 
objective cure rate were 64% and 69% respectively. Similarly, Zhang et al 
23
 showed the 7-years 
patient-reported success rate in the inside-out TO-TVT (n=62) to be 61.3%. Compared to the E-
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TOT, the latter 2-studies used a stricter definition for patient-reported success (no leakage). We 
did not find any significant differences in patient-reported outcomes between inside-out and 
outside-in TO-TVT; this is consistent with the current literature on shorter term outcomes
24
.    
 
The Cochrane review
25
 reported that the outcomes for all SUI procedures seem to decline 
overtime. Similar trend was seen in the E-TOT study with significant reduction in patient-
reported success rate at 9-years compared to 1-year, however the outcomes were relatively stable 
after 3-years. Similarly, 25 participants (8%) underwent further continence surgery; of those only 
1%(n=3) after the first 3-years. Based on the results of the E-TOT study, clinicians can 
confidently counsel women that successful outcomes at 3-years are most likely to be retained at 
9-years. In the E-TOT study, the re-operation rate was similar to the 7 and 7.8% reported by 
Ulrich etal
6
 and Aigmueller etal
21
 in 10-years following TO-TVT and RP-TVT respectively. 
However, other studies have reported higher re-operation rates following TO-TVT
19,26
.  
 
Multivariate analysis in the E-TOT study did not show any independent risk factors for late 
failures. Previous continence surgery and low maximum urethral-closure pressure were 
independent risk factors for TO-TVT failure at 1-year follow-up
8
. Recently, Serati et al
7 
found 
previous continence surgery to be the only risk factor for TO-TVT failure at 10-years follow-up. 
Lapis et al
27
  however showed that low-MUCP did not affect the success rates of repeat RP-TVT 
while a combination of low-MUCP and limited urethral mobility were associated with 
significantly reduced success rate. 
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Emphasis has been recently focused on the AE associated with the use of mesh in pelvic floor 
surgery. There is a general concern for possible under-reporting of AE; hence we analyzed the 
AE among respondents only to avoid such underestimation.  
- The rate of de-novo urgency in the E-TOT study was 9.6% at 9-years which were almost 
identical to 9.68% reported by Zhang et al
23
 at 7-years follow-up for the inside-out TO-TVT. 
Serati et al 
7 
reported a higher de-novo urgency rate (14%) at 10-years following inside-out 
TO-TVT, while Ulrich et al
6 
reported 26% at the same follow-up period. It’s well recognized 
that OAB symptoms tend to wax and wane and the incidence increase with age
28
. Hence on 
assessing urgency at long-term follow-up studies, it can be difficult to ascertain if it’s related 
to the MUS or the advancing age or is a progression of an underlying pathology.  
- Groin Pain: In the E-TOT study, 4% of the respondents reported groin or thigh 
pain/discomfort and were almost equally distributed between both TO-TVT approaches; only 
1.4% required either medical or surgical treatment. In some patients, the symptoms raise 
almost 6-7years after the operation leading to uncertainty on its relation to the procedure. The 
lack of a control group (without surgery) introduces further uncertainty. However chronic 
groin pain is a recognized AE for TO-TVT; Zhang et al
23
 and Ulrich et al
6
 reported 6.4% and 
9% groin/ inguinal pain/ discomfort at 7 and 10-years follow-up respectively. The current 
evidence therefore tends to confirm that TO-TVT are associated with long-term groin 
pain/discomfort.  Intractable suprapubic pain has also been previously described following 
colposuspension and known as post-colposuspension syndrome. Interestingly, a recent long-
term follow-up RCT comparing RP-TVT vs. autologous fascial slings (AFS) showed a 3.2% 
incidence of scar pain in the non-mesh alternative arm(AFS) , suggesting that chronic pain is 
not just a problem seen with mesh grafts
29
. 
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- Tape erosion/extrusion: our results are consistent with Ulrich et al al
6
 and Zhang et al
23
 
that vaginal tape erosion/extrusion can occur at a late stage; surgeons need to be vigilant for 
this possibility. In our experience, we treat tape extrusion with excision of the eroded part as 
we don’t find conservative treatment successful. Our results exclude possible asymptomatic 
tape erosions/extrusions.  
 
QoL and sexual function can be quite complicated to assess at LT follow-up as many other 
confounding factors may have developed in participants’ lives. The use of disease-specific 
questionnaires can help to overcome this issue to an extent. Similar to the E-TOT results at 1 and 
3 years, clinically significant improvement in women’s QoL was seen in the majority of women 
(76%) at median of 9-years follow-up. Our findings concur with Ulrich et al
6
 and Serrati et al
7
 
who reported significant improvement in most QoL domains at 10-years follow-up following 
TO-TVT. The current evidence therefore tends to confirm that successful outcome of TO-TVT 
can have a long-lasting positive effect on women’s QoL. 
 Only 87 women completed the sexual function questionnaire however this is the largest cohort 
assessing sexual function following TO-TVT at such long-term follow-up. The majority of 
women (61%) reported an improvement in sexual function however there is an apparent 
deterioration for one third of the participants. Several confounding factors may have occurred in 
that decade of follow-up that would inevitably impact women sexual function, such as advancing 
age, development of prolapse and menopausal vaginal dryness.  
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CONCLUSIONS: 
This is the largest and longest follow-up RCT of TO-TVT. TO-TVT is associated with 71.6% 
patient-reported success rate, 4% groin pain/discomfort and 8% continence re-operation rate for 
TO-TVT at median of 9-years follow-up; the success rate is almost stable after 3-years.  
 
Practical recommendations:  Patients’ can be counselled that the success rate for TO-TVT is 
almost stable after 3-years around 71% and the risk of chromic groin pain is 4% with 1.4% 
requiring medical or surgical treatment. 
 
Research recommendations: Qualitative study is required to assess those participants with pain 
for severity; relation to the procedure; impact on QoL and any regret. 
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Table 1: Primary Outcome at 9 years follow-up 
 Whole cohort  TOT (Outside-
in) 
TVT-O (Inside-
out) 
OR (95% CI) p-value 
PGI-I success♥ 149/208 
(71.63%) 
76/104 
(73.1%)  
73/104 (70.2%)  0.867 
(0.474,1.586) 
 
0.760 
Assume all missing 
data as failure  
150/307 
(48.9%) 
77/151 
(51.0%) 
73/156 (46.8%) 0.85 (0.54,1.32) 0.534 
Assume all missing 
data as success 
249/307 
(80.1%) 
124/151 
(82.1%) 
125/156 (80.1%) 0.88(0.49, 1.56) 0.764 
Last observation 
carried forward  
223/307 
(72.6%) 
114/151 
(75.5%) 
109/156 (69.9%) 1.33 (0.80, 2.20) 0.288 
 
♥Patient Global Impression of Improvement: Success defined as Very/Much Improved.  
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Table 2: Late Adverse Events   
  TO-TVT Cohort (n=208)
♥
 
De-Novo Urgency (n=20) 9.61% 
CISC (Clean Intermittent Self 
Catheterisation) 
(n=2) 0.96%  
Long-term Low-dose 
Antibiotics 
(n-3) 1.44% 
Late Vaginal Extrusions (n=4) 1.92% 
Any Groin/ Thigh/ Vaginal Pain 
* 
(n=9) 4.32% 
Type 
of 
Tape 
Age 
at 9 
year 
FU 
Further 
incontinence/ 
prolapse  surgery 
within last 9 years 
PGI-I Outcome Pain Site Treatment and Patients Comments 
TOT 50 Repeat TVT-O Success (Very 
Much Improved) 
Not Specified Pain-killers and antibiotics. Very 
Painful and always take infections 
down below.  
TOT 55 NO Success (Much 
Improved) 
Back ache and 
Groin 
Started in the last 6 month to have 
groin and back ache. No treatment* 
TOT 54 NO Failed (Much 
Worse) 
Not Specified Co-codamol-can't take Diazepam 
due to my Job and amitriptyline 
makes me sick 
TOT 47 NO Failed (Very Much 
Worse) 
Not Specified No treatment.* 
TOT 62 NO Failed (Same) Groin & Thigh Not sure if related, my doctor 
referred me to the hospital. No 
treatment* 
TVT-
O 
55 NO Success (Much 
Improved) 
Back ache and 
Right Groin 
No treatment* 
TVT-
O 
65 Excision of Tape Failed (Much 
Worse) 
Not Specified I had most of it removed for 
something growing over it – Take 
co-codamol for arthritis which 
helps.♣ 
TVT-
O 
48 NO Failed (Improved) Left Groin and left 
side of Stomach 
IBS Worsened over last 4-years and 
will have hysterectomy. No 
treatment * 
TVT-
O 
49 NO Failed (Much 
Worse) 
Not Specified No treatment * 
♣ On checking records; she had almost total excision of TVT-O (vaginal portion and up-to obturator 
muscle) due to erosion in lateral vaginal sulcus with growing granulation tissue on top and tenderness.  
She had a background of arthritis for which she was already on regular analgesia. 
*Patients are not receiving any treatment for pain. 
♥AE were assessed among respondents only (n=208), as one single cohort.  
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Recruited & Randomised (n= 341) 
Allocated to and Received Inside -Out (TVT-O 
™) (n = 170) 
                    
 
Completed 6 month Follow-up (n = 160) 
 
Withdrawn (n=6) 
*Untraceable (n=1) 
♣Repeated failure to respond (n=3) 
Allocated to and Received Outside-In (ARIS) (n 
= 171) 
 
 
Completed 6 month Follow-up (n = 157) 
 
Withdrawn (n=8) 
*Untraceable (n=4) 
♣Repeated failure to respond (n=2) 
 
 
Completed 1- Y r Follow-up (n = 152) 
 
Unplanned Pregnancy (n=1)  
Prolapse surgery (n=1) 
*Untraceable (n=1) 
♣Repeated failure to respond (n=5) 
Completed 1-Y ar Follow-up (n = 147) 
 
Moved abroad (n=1)  
Receiving Chemotherapy for Ovarian CA (n=1) 
♣Repeated failure to respond (n=8) 
Declined process of 
follow-up (n= 3) 
Completed 3-Years Follow-up (n = 112) 
 
*Untraceable (n=21)  
Withdrew (n=4) 
♣Repeated failure to respond (n=10) 
Completed 3- Years Follow-up (n = 126) 
 
*Untraceable (n=10) 
Withdrew (n=6) 
♣Repeated failure to respond (n=10) 
Eligible for the study (n= 344)  
Completed 9-Years Follow-up (n = 104) 
 
*Untraceable (n=2)  
Withdrew (n=1) 
♣Repeated failure to respond (n=3) 
Deceased (n=2) 
Completed 9-Years Follow-up (n = 104) 
 
*Untraceable (n=8)  
Withdrew (n=2) 
♣Repeated failure to respond (n=10) 
Deceased (n=2) 
Figure 1: Flow Chart of recruited patients & follow-up  
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*Postal questionnaires returned as in-correct address and correct address could not be established (e.g. 
patient moved address, moved abroad, etc )  
 
♣Participant failed to respond to follow-up questionnaires however her correct postal address was 
confirmed.  
 
 
 
Figure 2A: Patient-reported success rate with TO-TVT over the period of follow-up  
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Figure 2 B: Cumulative    Repeat    Continence    Surgery    over the period of follow-up  
 
